The evolving HIV/AIDS response and the urgent tasks ahead

Health Affairs

Volumn 28, Issue 6, 2009, Pages 1578-1590

  Bertozzi, Stefano M ^a   Martz, Tyler E ^b   Piot, Peter ^c  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

^b Center for Evaluation Research and Surveys

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; ECONOMIC ASPECT; HEALTH CARE FINANCING; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; PREVALENCE; SCALE UP;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; HEALTH CARE COSTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERNATIONALITY; PREVENTIVE HEALTH SERVICES; UNITED STATES;

EID: 77952215269     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.6.1578     Document Type: Conference Paper

References (32)

1. Merson MH, O'Malley J, Serwadda D, Apisuk C. The history and challenge of HIV prevention. Lancet. 2008;377(9637):475-88.
2. Van de Perre P, Rouvroy D, Lepage P, Bogaerts J, Kestelyn P, Kayihigi J, et al. Acquired immunodeficiency syndrome in Rwanda. Lancet. 1984;2(8394):62-5.
3. Piot P, Quinn TC, Taelman H, Feinsod FM, Minlangu KB, Wobin O, et al. Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet. 1984;2(8394):65-9.
4. United States Agency for International Development. What happened in Uganda? Declining HIV prevalence, behavior change, and the national response. Hogel JA, editor. Washington (DC): USAID; 2002 Sep.
5. World Health Organization Global Programme on AIDS. Progress report number 5 [Internet]. Geneva (Switzerland): WHO; 1989 May [cited 2009 Sep 22]. Available from: http://whqlibdoc.who.int/HQ/1989/WHO-GPA-DIR-89.4.pdf
6. Protest over AZT price led to the arrest of 19. New York Times. 2009 Feb 9.
7. Lemp GF, Payne SF, Neal DP, Rutherford GW. The effect of zidovudine (AZT) on survival of AIDS patients in San Francisco. Paper presented at: Fifth International Conference on AIDS; 1989 Jun 4-9; Montreal, Quebec. Abstract no. W.B.P.354 [cited 2009 Sep 22]. Available from: http://gateway.nlm.nih.gov/ MeetingAbstracts/ma?f=102177987.html
8. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in nairobi prostitutes. JAMA. 1992;268(4):477-82.
9. World Health Organization Global Programme on AIDS. The HIV/AIDS pandemic: 1994 overview [Internet]. Geneva (Switzerland): WHO; 1994 [cited 2009 Sep 30]. Available from: http://whqlibdoc.who.int/hq/1994/WHO-GPA-TCO-SEF-94.4. pdf
10. Knight L. UNAIDS. The first ten years [Internet]. Geneva (Switzerland): UNAIDS; 2008 May [cited 2009 Sep 25]. Available from: http://data.unaids.org/ pub/Report/2008/JC1579-First-10-years-en.pdf
11. Connor E, Sperling R, Gelber R, Kiseley P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331(18):1173-80.
12. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346(8974):530-6.
13. Markowitz M, Cao Y, Hurley A, O'Donovan R, Peterkin J, Anderson B, et al. Triple therapy with AZT and 3TC in combination with nelfinavir mesylate in 12 antiretroviral-naïve subjects chronically infected with HIV-1. Paper presented at: 11th International Conference on AIDS; 1996 Jul 7-12; Vancouver, British Columbia. Abstract no. LBB.B.6031.
14. UNAIDS. Report on the global HIV/AIDS epidemic 1998 [Internet]. Geneva (Switzerland): UNAIDS; 1998 Jun [cited 2009 Sep 22]. Available from: http://data.unaids.org/pub/Report/1998/9981125-global-epidemic-report-en.pdf
15. U.S. Food and Drug Administration. Antiretroviral drugs used in the treatment of HIV infection [Internet]. Rockville (MD): FDA; 2009 May 20 [cited 2009 Sep 22]. Available from: http://www.fda.gov/ForConsumers/byAudience/ ForPatientAdvocates/HIVandAiDSActivities/ucm118915.htm
16. President's Emergency Plan for AIDS Relief [Internet]. Washington (DC): PEPFAR; [cited 2009 Sep 22]. Available from http://www.pepfar.gov/about/index. htm
17. UNAIDS [Internet]. Geneva (Switzerland): UNAIDS. Press statement, UNAIDS APPLAUDS Clinton Foundation's agreement with pharmaceutical companies to cut prices of AIDS drugs; 2003 Oct 23 [cited 2009 Sep 22]. Available from http://data.unaids.org/Media/Press-Statements01/clinton-ps-23Oct03-en.pdf
18. World Health Organization. The 3 by 5 initiative [Internet]. Geneva (Switzerland): WHO/UNAIDS; c2009 [cited 2009 Sep 22]. Available from http://wwwwho.int/3by5
19. Underhill K, Montgomery P, Operario D. Sexual abstinence only programmes to prevent HIV infection in high income countries: systematic review. BMJ. 2007;335(7613):248.
20. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998;339(8):504-10.
21. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360(9338):971-7.
22. UNAIDS. 2006 report on the global AIDS epidemic. Geneva (Switzerland): UNAIDS; 2006 May.
23. Dobard C, Parikh U, Sharma S, Cong ME, Smith J, Garcia-Lerma G, et al. Complete protection against repeated vaginal simian HIV exposure in macaques by a topical gel containing tenofovir alone or with emtricitabine. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Quebec; 2009 Feb 8-11. Abstract no. 46.
24. Karim SA, Coletti A, Richardson B, Ramjee G, Hoffman I, Chirenje M, et al. Safety and effectiveness of vagi7 nal microbicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. Paper presented at 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Quebec; 2009 Feb 8-11. Abstract no. 48LB.
25. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562):643-56.
26. Gray RH, Kigozi G, Serwadda D, Makumbi F, Wataya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657-66.
27. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk the ANRS 1265 trial. PLoS Med. 2005;2(11):e298.
28. A pilot study of pre-exposure prophylaxis (PrEP) to evaluate safety, acceptability, and adherence in at-risk populations in Uganda, Africa [Internet]. Study no. NCT00931346. Bethesda (MD): National Institutes of Health; [updated 2009 Sep 2] [cited 2009 Sep 22]. Available from http://clinicaltrials. gov/ct2/show/NCT00931346
29. Botswana TDF/FTC oral HIV prophylaxis trial [Internet]. Study no. NCT00448669. Bethesda (MD): National Institutes of Health; [updated 2007 Apr 2] [cited 2009 Sep 22] Available from http://clinicaltrials.gov/ct2/show/ NCTC00448669?term=Botswana&rank=1
30. U.S. Military HIV Research Program [Internet]. Washington (DC): MHRP; c2009. Press release, HIV vaccine study first to show some effectiveness in preventing HIV; 2009 Sep 24 [cited 2009 Oct 5]. Available from:https://www01. hjf.org/apps/internet/hivnewscenter.nsf/phase3pressrelease
31. UNAIDS. 2008 report on the global AIDS epidemic. Geneva (Switzerland): UNAIDS; 2008 Aug.
32. Nasar S. U.S. output per worker is growing. New York Times. 1992 Nov 27.